BATTLE: Biomarker-Based Approaches of Targeted Therapy for Lung Cancer Elimination
Abstract
Lung cancer is the leading cause of cancer-related death in both men and women in the United States. Chemotherapy has reached its limit in improving the survival of lung cancer patients. Therefore, a different strategy must be waged in the battle against lung cancer. Targeted therapy, a newly emerged therapeutic approach in lung cancer, has succeeded in some cancer types and demonstrated its initial success in the treatment of lung cancer when a class of targeted agents termed epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib and erlotinib, improved tumor response rates in patients with advanced nonsmall cell lung cancer (NSCLC), which was strongly correlated to the presence of EGFR mutations in the tumors (Cappuzzo and Hirsch et al., 2004; Cappuzzo and Magrini et al., 2004; Gatzemeier et al., 2004; Herbst and Giaccone et al., 2004; Herbst and Prager et al., 2004; Herbst and Sandler et al., 2004; Lynch et al., 2004; Kobayashi et al., 2005; Miller et al., 2004; Pao et al., 2004; Paez et al., 2004; Shepherd et al., 2004; Shigematsu et al., 2005). This has for the first time demonstrated the importance of selecting patients for individualized targeted therapy in NSCLC.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2008
- Accession Number
- ADA485729
Entities
People
- Edward Kim
- Li Mao
- Roy Herbst
- Waun Ki Hong
Organizations
- The University of Texas MD Anderson Cancer Center